Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide vs Insulin Glargine in Type 2 Diabetes
NCT00099619Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2004
- Primary completion
- Aug 2005
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in glycosylated hemoglobin at 32 weeks. Started Sep 2004; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00099619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099619.